Tafamidis Meglumine

As for the prospect of facing sooner-than-expected generic pricing pressure from Vyndaqel copycats in Europe, BridgeBio CEO Neil Kumar said that his company is counting on continued efforts to set Attruby apart from Pfizer's tafamidis franchise. Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax franchise. All told, the BridgeBio drug's sales scaled upward each earnings period last year, reaching $146 million in the fourth quarter, representing a 35% sequential increase. Still, the cardiomyopathy drug's gains are tempered slightly by a recent move by BridgeBio's rival that rattled investors. Three weeks ago, Pfizer withdrew a patent in Europe that protects its compound tafamidis—known as Vyndaqel in Europe—opening the possibility of generic pricing pressure on Attruby by 2028, and BridgeBio's share price fell by 15%. In turn, BridgeBio used its earnings presentation Tuesday to give investors a dose of reassurance, laying out its expectations on generic tafamidis pressure in Europe and providing more evidence of Attruby's strong launch. While BridgeBio already reported its preliminary fourth quarter sales last month, the company this week filled in some of the blanks on Attruby's growing momentum, noting that 7,804 prescriptions had been written for its drug as of Feb. 20, 2026. Based on that stat, analysts from Mizuho Securities calculated that Attruby is attracting an average of 161 new patients per week, up from some some 143 in January.  “Management noted that this acceleration can be explained by a rapid patient identification, plus prescribers responding to Attruby’s data being put forth,” the Mizuho team wrote, adding that “continued acceleration” should “reinforce” Attruby’s profile. For the full year 2025, Attruby generated sales of $362 million, with 40% of that revenue collected in the fourth quarter. BridgeBio added that its $146 million sales for Attruby in the fourth quarter suggest that the treatment is attracting more than 25% of new patient starts in its cardiomyopathy indication.Analysts from Evercore ISI further highlighted the recent “prescribing momentum” of Attruby in a note to clients this week, adjusting their 2026 worldwide sales projection for the oral medication from $828 million to $1.02 billion. Evercore also increased its peak sales forecast for Attruby from $2.9 billion to $3.5 billion.  As for the prospect of facing sooner-than-expected generic pricing pressure from Vyndaqel copycats in Europe, BridgeBio CEO Neil Kumar said that his company is counting on continued efforts to set Attruby apart from Pfizer's tafamidis franchise.“We have a vastly superior enthalpic binding mode than does tafamidis, which in concert with superior binding kinetics continues to reinforce Attruby’s better stabilization profile,” Kumar said on an analyst call this week. “A recent bevy of literature further supports that increases in serum (transthyretin) are associated reliably with decreases in the relative risk of mortality.” “It is important to separate two things: the legal process around tafamidis and the fundamental strength of Attruby," he added. "Our confidence in Attruby is rooted in its clinical profile and market positioning, not a particular IP outcome,” said Kumar, who added that Pfizer’s withdrawal of its patent was “unexpected.” During the Q&A portion of his company's earnings call, Kumar cited other indications—including pulmonary arterial hypertension, statins and prostate cancer—where second-to-market drugs continued to grow even after the first-to-market product lost its exclusivity.  “We believe physicians are making decisions based on clinical performance, not simply price, and prescribing trends we are seeing are reflecting that,” Kumar said. “Even in a hypothetical scenario involving generic tafamidis, we do not believe a less efficacious product would undermine the role of a clinically differentiated therapy in a serious, progressive disease like ATTR cardiomyopathy.”